Gossamer Bio

Yahoo Finance • 2 months ago

Presenting on the Emerging Growth Conference 75 Day 2 on September 26

Emerging Growth MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 75th Emerging Growth Conference on September 25 & 26, 2024. The Emerging Growth Con... Full story

Yahoo Finance • 11 months ago

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

SAN DIEGO, December 13, 2023--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertensi... Full story

Yahoo Finance • 12 months ago

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

- Mr. Smith is a recognized leader in the commercialization of PAH products, most recently leading sotatercept US pre-launch activities at Merck - - Previously, Mr. Smith led US sales operations for Actelion - SAN DIEGO, December 05, 202... Full story

Yahoo Finance • last year

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Gossamer Bio, Inc. (NASDAQ: GOSS) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Gossamer Bio, Inc. (NASDAQ: GOSS) on behalf of the company’s investors. Since December 2022, shares of Gossamer’s common stock have decli... Full story

Yahoo Finance • last year

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Gossamer Bio, Inc.; Urges Gossamer Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, Conn., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Gossamer Bio, Inc. (Nasdaq: GOSS) (“Gossamer” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determine whether Go... Full story

Yahoo Finance • 2 years ago

Bullish insiders at Gossamer Bio, Inc. (NASDAQ:GOSS) loaded up on US$1.2m of stock earlier this year

In the last year, multiple insiders have substantially increased their holdings of Gossamer Bio, Inc. (NASDAQ:GOSS) stock, indicating that insiders' optimism about the company's prospects has increased. While insider transactions are not... Full story

Yahoo Finance • 2 years ago

Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer

CARLSBAD, Calif., October 31, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that... Full story

Yahoo Finance • 2 years ago

‘Squeezable’ AMC, GameStop stocks break out to multi-month highs

Shares of both AMC Entertainment Holdings Inc. and GameStop Corp. surged to multi-month highs Wednesday, as they extended breakouts above previous chart resistance levels.... Full story

Yahoo Finance • 2 years ago

The Co-Founder of Gossamer Bio, Inc. (NASDAQ:GOSS), Faheem Hasnain, Just Bought 3.8% More Shares

Gossamer Bio, Inc. (NASDAQ:GOSS) shareholders (or potential shareholders) will be happy to see that the Co-Founder, Faheem Hasnain, recently bought a whopping US$1m worth of stock, at a price of US$7.21. While that only increased their hol... Full story

Yahoo Finance • 3 years ago

Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update

- Seralutinib (GB002) completed PAH patient enrollment in Phase 2 TORREY Study - - Topline results from Phase 2 TORREY Study expected in the fourth quarter of 2022 - - Cash, cash equivalents & marketable securities totaled $272 million a... Full story